King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.

JUPITER, Fla. and FREEHOLD, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (“Ligand”) (Nasdaq: LGND) and Channel Therapeutics ...

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL ...

胰腺导管腺癌(PDAC)缺乏特异性诊断标志物，尤其对CA19-9阴性患者存在检测盲区。南京鼓楼医院团队通过多组学分析发现CD44在CA19-9阴性PDAC中高表达，开发了放射性标记抗体89Zr-1M2E3实现精准影像诊断，为这类高恶性度肿瘤提供了新型诊疗靶点。 胰腺癌被称为"癌中 ...

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo ...

Ligand and investors are contributing $50 million to support the Pelthos-Channel merger, set to close summer 2025. FDA-approved Zelsuvmi is the first at-home prescription for molluscum, a skin ...

为解决免疫疗法（如免疫检查点抑制剂 ICIs）缺乏有效预后生物标志物的问题，研究人员开展了关于癌症干细胞标志物 CD44 在 33 种人类癌症中预后价值及免疫功能的研究。结果发现 CD44 与肿瘤分期、预后及免疫微环境相关，可作为潜在免疫治疗靶点和生物标志物。

ADAM10-EVs: Regulate cell proliferation and adhesion by targeting Notch-1 and CD44 receptors, which contribute to tumour progression ... transforming growth factor beta 1 (TGF-β1) and programmed death ...

Florida biopharma Ligand Pharmaceuticals (Nasdaq: LGND) subsidiary Pelthos Therapeutics is to merge with Channel Therapeutics (NYSE American: CHRO), a developer of non-opioid pain treatments. The ...